Patents by Inventor David Hume

David Hume has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20010041363
    Abstract: A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and/or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.
    Type: Application
    Filed: February 28, 2001
    Publication date: November 15, 2001
    Applicant: University of Michigan
    Inventor: H. David Humes
  • Publication number: 20010001817
    Abstract: Disclosed is an implantable device for delivering a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation. The device comprises a blood permeable element that can be anchored to an inner wall of an intact blood vessel The device also comprises a capsule that is held in place within the blood vessel by the anchored blood permeable element. The capsule encloses viable cells which produce and secrete the pre-selected molecule into blood passing the capsule. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel the device of the invention.
    Type: Application
    Filed: December 12, 2000
    Publication date: May 24, 2001
    Inventor: H. David Humes
  • Patent number: 6150164
    Abstract: A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and/or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: November 21, 2000
    Assignee: The Regents of the University of Michigan
    Inventor: H. David Humes
  • Patent number: 6060270
    Abstract: Methods, including culture media conditions, which provide for isolation and purification of renal tubule stem cells and for in vitro kidney tubulogenesis are disclosed. The methods rely on culturing adult kidney cells in a culture media treated with combinations of transforming growth factor-.beta..sub.1, epidermal growth factor, and all-trans retinoic acid.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 9, 2000
    Assignee: The University of Michigan
    Inventor: H. David Humes
  • Patent number: 5911704
    Abstract: Disclosed is an implantable device for delivering a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation. The device comprises a blood permeable element that can be anchored to an inner wall of an intact blood vessel. The device also comprises a capsule that is held in place within the blood vessel by the anchored blood permeable element. The capsule encloses viable cells which produce and secrete the preselected molecule into blood passing the capsule. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel the device of the invention.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: June 15, 1999
    Assignee: Nephros Therapeutics, Inc.
    Inventor: H. David Humes
  • Patent number: 5704910
    Abstract: Disclosed is an implantable device for delivering a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation. The device comprises a blood permeable element that can be anchored to an inner wall of an intact blood vessel. The device also comprises a capsule that is held in place within the blood vessel by the anchored blood permeable element. The capsule encloses viable cells which produce and secrete the pre-selected molecule into blood passing the capsule. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel the device of the invention.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 6, 1998
    Assignee: Nephros Therapeutics, Inc.
    Inventor: H. David Humes
  • Patent number: 5686289
    Abstract: A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Renal cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure as well as studying renal tubululogenesis in vitro.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 11, 1997
    Assignee: The University of Michigan
    Inventors: H. David Humes, Deborah A. Cieslinski
  • Patent number: 5549674
    Abstract: A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Renal cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure as well as studying renal tubululogenesis in vitro.
    Type: Grant
    Filed: October 8, 1993
    Date of Patent: August 27, 1996
    Assignee: The Regents of The University of Michigan
    Inventors: H. David Humes, Deborah A. Cieslinski
  • Patent number: 5429938
    Abstract: Methods, including culture media conditions, which provide for isolation and purification of renal tubule stem cells and for in vitro kidney tubulogenesis are disclosed. The methods rely on culturing adult kidney cells in a culture media treated with combinations of transforming growth factor-.beta..sub.1, epidermal growth factor, and all-trans retinoic acid.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: July 4, 1995
    Assignee: University of Michigan
    Inventor: H. David Humes
  • Patent number: 5360790
    Abstract: The therapy of patients with nephrotoxic or ischemic acute renal failure with epidermal growth factor and/or transforming growth factor-.alpha. is disclosed.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: November 1, 1994
    Assignee: The Regents of the University of Michigan
    Inventor: H. David Humes